PandemieGrippaleV1, PascalFrancis, Corpus, bibRecord, 000025

In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate

Identifieur interne : 000025 ( PascalFrancis/Corpus ); précédent : 000024; suivant : 000026

In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate

Auteurs : Natalia A. Ilyushina ; Raymond P. Donnelly

Source :

Antiviral research [ 0166-3542 ] ; 2014.

RBID : Pascal:14-0273479

Descripteurs français

Pascal (Inist)
- In vitro, Grippe A, Cytokine, Interféron bêta, Oséltamivir, Virus grippal A, Traitement associé, Association médicamenteuse, Antiviral.

English descriptors

KwdEn :
- Antiviral, Beta interferon, Combined treatment, Cytokine, Drug combination, In vitro, Influenza A, Influenza A virus, Oseltamivir.

Abstract

Influenza viruses, which can cross species barriers and adapt to new hosts, pose a constant potential threat to human health. The influenza pandemic of 2009 highlighted the rapidity with which an influenza virus can spread worldwide. Currently available antivirals have a number of limitations against influenza, and novel antiviral strategies, including novel drugs and drug combinations, are urgently needed. Here, we evaluated the in vitro effects of interferon (IFN)-β, IFN-λ1, oseltamivir carboxylate (a neuraminidase (NA) inhibitor), and combinations of these agents against two seasonal (i.e., H1N1 and H3N2) influenza A viruses. We observed that A/California/04/09 (H1N1) and A/Panama/2007/99 (H3N2) isolates were equally sensitive to the antiviral activity of IFN-β and oseltamivir carboxylate in A549 and Calu-3 cells. In contrast, IFN-λ1 exhibited substantially lower protective potential against the H1N1 strain (64-1030-fold ↓, P < 0.05), and was ineffective against H3N2 virus in both cell lines. Three dimensional analysis of drug-drug interactions revealed that IFN-λ1 interacted with IFN-β and oseltamivir carboxylate in an additive or synergistic manner, respectively, to inhibit influenza A virus replication in human airway epithelial cells. Overall, the present study demonstrated that anti-influenza agents with different mechanisms of action (e.g., a NA inhibitor combined with IFN-λ1) exerted a significantly greater (P < 0.05) synergistic effect compared to co-treatment with drugs that target the same signaling pathway (i.e., IFN-β plus IFN-λ1) in vitro. Our findings provide support for the combined use of interferon plus oseltamivir as a potential means for treating influenza infections.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0166-3542`
A02	`01`			`@0 ARSRDR`
A03		`1`		`@0 Antivir. res.`
A05				`@2 111`
A08	`01`	`1`	`ENG`	`@1 In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate`
A11	`01`	`1`		`@1 ILYUSHINA (Natalia A.)`
A11	`02`	`1`		`@1 DONNELLY (Raymond P.)`
A14	`01`			`@1 Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration @2 Silver Spring, MD 20993 @3 USA @Z 1 aut. @Z 2 aut.`
A20				`@1 112-120`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 18839 @5 354000502689950160`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 3/4 p.`
A47	`01`	`1`		`@0 14-0273479`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Antiviral research`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Influenza viruses, which can cross species barriers and adapt to new hosts, pose a constant potential threat to human health. The influenza pandemic of 2009 highlighted the rapidity with which an influenza virus can spread worldwide. Currently available antivirals have a number of limitations against influenza, and novel antiviral strategies, including novel drugs and drug combinations, are urgently needed. Here, we evaluated the in vitro effects of interferon (IFN)-β, IFN-λ1, oseltamivir carboxylate (a neuraminidase (NA) inhibitor), and combinations of these agents against two seasonal (i.e., H1N1 and H3N2) influenza A viruses. We observed that A/California/04/09 (H1N1) and A/Panama/2007/99 (H3N2) isolates were equally sensitive to the antiviral activity of IFN-β and oseltamivir carboxylate in A549 and Calu-3 cells. In contrast, IFN-λ1 exhibited substantially lower protective potential against the H1N1 strain (64-1030-fold ↓, P < 0.05), and was ineffective against H3N2 virus in both cell lines. Three dimensional analysis of drug-drug interactions revealed that IFN-λ1 interacted with IFN-β and oseltamivir carboxylate in an additive or synergistic manner, respectively, to inhibit influenza A virus replication in human airway epithelial cells. Overall, the present study demonstrated that anti-influenza agents with different mechanisms of action (e.g., a NA inhibitor combined with IFN-λ1) exerted a significantly greater (P < 0.05) synergistic effect compared to co-treatment with drugs that target the same signaling pathway (i.e., IFN-β plus IFN-λ1) in vitro. Our findings provide support for the combined use of interferon plus oseltamivir as a potential means for treating influenza infections.
C02	`01`	`X`		`@0 002B02S05`
C02	`02`	`X`		`@0 002B05C02C`
C03	`01`	`X`	`FRE`	`@0 In vitro @5 01`
C03	`01`	`X`	`ENG`	`@0 In vitro @5 01`
C03	`01`	`X`	`SPA`	`@0 In vitro @5 01`
C03	`02`	`X`	`FRE`	`@0 Grippe A @5 02`
C03	`02`	`X`	`ENG`	`@0 Influenza A @5 02`
C03	`02`	`X`	`SPA`	`@0 Gripe A @5 02`
C03	`03`	`X`	`FRE`	`@0 Cytokine @5 03`
C03	`03`	`X`	`ENG`	`@0 Cytokine @5 03`
C03	`03`	`X`	`SPA`	`@0 Citoquina @5 03`
C03	`04`	`X`	`FRE`	`@0 Interféron bêta @2 FR @5 04`
C03	`04`	`X`	`ENG`	`@0 Beta interferon @2 FR @5 04`
C03	`04`	`X`	`SPA`	`@0 Interferón beta @2 FR @5 04`
C03	`05`	`X`	`FRE`	`@0 Oséltamivir @2 NK @2 FR @5 05`
C03	`05`	`X`	`ENG`	`@0 Oseltamivir @2 NK @2 FR @5 05`
C03	`05`	`X`	`SPA`	`@0 Oseltamivir @2 NK @2 FR @5 05`
C03	`06`	`X`	`FRE`	`@0 Virus grippal A @2 NW @5 06`
C03	`06`	`X`	`ENG`	`@0 Influenza A virus @2 NW @5 06`
C03	`06`	`X`	`SPA`	`@0 Influenza A virus @2 NW @5 06`
C03	`07`	`X`	`FRE`	`@0 Traitement associé @5 07`
C03	`07`	`X`	`ENG`	`@0 Combined treatment @5 07`
C03	`07`	`X`	`SPA`	`@0 Tratamiento asociado @5 07`
C03	`08`	`X`	`FRE`	`@0 Association médicamenteuse @5 08`
C03	`08`	`X`	`ENG`	`@0 Drug combination @5 08`
C03	`08`	`X`	`SPA`	`@0 Asociación medicamentosa @5 08`
C03	`09`	`X`	`FRE`	`@0 Antiviral @5 23`
C03	`09`	`X`	`ENG`	`@0 Antiviral @5 23`
C03	`09`	`X`	`SPA`	`@0 Antiviral @5 23`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
C07	`03`	`X`	`FRE`	`@0 Influenzavirus A @2 NW`
C07	`03`	`X`	`ENG`	`@0 Influenzavirus A @2 NW`
C07	`03`	`X`	`SPA`	`@0 Influenzavirus A @2 NW`
C07	`04`	`X`	`FRE`	`@0 Orthomyxoviridae @2 NW`
C07	`04`	`X`	`ENG`	`@0 Orthomyxoviridae @2 NW`
C07	`04`	`X`	`SPA`	`@0 Orthomyxoviridae @2 NW`
C07	`05`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`05`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`05`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`06`	`X`	`FRE`	`@0 Exo-α-sialidase @2 FE @5 37`
C07	`06`	`X`	`ENG`	`@0 Exo-α-sialidase @2 FE @5 37`
C07	`06`	`X`	`SPA`	`@0 Exo-α-sialidase @2 FE @5 37`
C07	`07`	`X`	`FRE`	`@0 Glycosidases @2 FE`
C07	`07`	`X`	`ENG`	`@0 Glycosidases @2 FE`
C07	`07`	`X`	`SPA`	`@0 Glycosidases @2 FE`
C07	`08`	`X`	`FRE`	`@0 Glycosylases @2 FE`
C07	`08`	`X`	`ENG`	`@0 Glycosylases @2 FE`
C07	`08`	`X`	`SPA`	`@0 Glycosylases @2 FE`
C07	`09`	`X`	`FRE`	`@0 Hydrolases @2 FE`
C07	`09`	`X`	`ENG`	`@0 Hydrolases @2 FE`
C07	`09`	`X`	`SPA`	`@0 Hydrolases @2 FE`
C07	`10`	`X`	`FRE`	`@0 Enzyme @2 FE`
C07	`10`	`X`	`ENG`	`@0 Enzyme @2 FE`
C07	`10`	`X`	`SPA`	`@0 Enzima @2 FE`
C07	`11`	`X`	`FRE`	`@0 Inhibiteur enzyme @5 38`
C07	`11`	`X`	`ENG`	`@0 Enzyme inhibitor @5 38`
C07	`11`	`X`	`SPA`	`@0 Inhibidor enzima @5 38`
C07	`12`	`X`	`FRE`	`@0 Inhibiteur neuraminidase @2 FR @5 39`
C07	`12`	`X`	`ENG`	`@0 Neuraminidase inhibitor @2 FR @5 39`
C07	`12`	`X`	`SPA`	`@0 Inhibidor neuraminidas @2 FR @5 39`
N21				`@1 342`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0273479 INIST
ET :	In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate
AU :	ILYUSHINA (Natalia A.); DONNELLY (Raymond P.)
AF :	Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration/Silver Spring, MD 20993/Etats-Unis (1 aut., 2 aut.)
DT :	Publication en série; Niveau analytique
SO :	Antiviral research; ISSN 0166-3542; Coden ARSRDR; Royaume-Uni; Da. 2014; Vol. 111; Pp. 112-120; Bibl. 3/4 p.
LA :	Anglais
EA :	Influenza viruses, which can cross species barriers and adapt to new hosts, pose a constant potential threat to human health. The influenza pandemic of 2009 highlighted the rapidity with which an influenza virus can spread worldwide. Currently available antivirals have a number of limitations against influenza, and novel antiviral strategies, including novel drugs and drug combinations, are urgently needed. Here, we evaluated the in vitro effects of interferon (IFN)-β, IFN-λ1, oseltamivir carboxylate (a neuraminidase (NA) inhibitor), and combinations of these agents against two seasonal (i.e., H1N1 and H3N2) influenza A viruses. We observed that A/California/04/09 (H1N1) and A/Panama/2007/99 (H3N2) isolates were equally sensitive to the antiviral activity of IFN-β and oseltamivir carboxylate in A549 and Calu-3 cells. In contrast, IFN-λ1 exhibited substantially lower protective potential against the H1N1 strain (64-1030-fold ↓, P < 0.05), and was ineffective against H3N2 virus in both cell lines. Three dimensional analysis of drug-drug interactions revealed that IFN-λ1 interacted with IFN-β and oseltamivir carboxylate in an additive or synergistic manner, respectively, to inhibit influenza A virus replication in human airway epithelial cells. Overall, the present study demonstrated that anti-influenza agents with different mechanisms of action (e.g., a NA inhibitor combined with IFN-λ1) exerted a significantly greater (P < 0.05) synergistic effect compared to co-treatment with drugs that target the same signaling pathway (i.e., IFN-β plus IFN-λ1) in vitro. Our findings provide support for the combined use of interferon plus oseltamivir as a potential means for treating influenza infections.
CC :	002B02S05; 002B05C02C
FD :	In vitro; Grippe A; Cytokine; Interféron bêta; Oséltamivir; Virus grippal A; Traitement associé; Association médicamenteuse; Antiviral
FG :	Virose; Infection; Influenzavirus A; Orthomyxoviridae; Virus; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Inhibiteur enzyme; Inhibiteur neuraminidase
ED :	In vitro; Influenza A; Cytokine; Beta interferon; Oseltamivir; Influenza A virus; Combined treatment; Drug combination; Antiviral
EG :	Viral disease; Infection; Influenzavirus A; Orthomyxoviridae; Virus; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Enzyme inhibitor; Neuraminidase inhibitor
SD :	In vitro; Gripe A; Citoquina; Interferón beta; Oseltamivir; Influenza A virus; Tratamiento asociado; Asociación medicamentosa; Antiviral
LO :	INIST-18839.354000502689950160
ID :	14-0273479

Links to Exploration step

Pascal:14-0273479

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate</title>
<author><name sortKey="Ilyushina, Natalia A" sort="Ilyushina, Natalia A" uniqKey="Ilyushina N" first="Natalia A." last="Ilyushina">Natalia A. Ilyushina</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration</s1>
<s2>Silver Spring, MD 20993</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Donnelly, Raymond P" sort="Donnelly, Raymond P" uniqKey="Donnelly R" first="Raymond P." last="Donnelly">Raymond P. Donnelly</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration</s1>
<s2>Silver Spring, MD 20993</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0273479</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0273479 INIST</idno>
<idno type="RBID">Pascal:14-0273479</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000025</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate</title>
<author><name sortKey="Ilyushina, Natalia A" sort="Ilyushina, Natalia A" uniqKey="Ilyushina N" first="Natalia A." last="Ilyushina">Natalia A. Ilyushina</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration</s1>
<s2>Silver Spring, MD 20993</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Donnelly, Raymond P" sort="Donnelly, Raymond P" uniqKey="Donnelly R" first="Raymond P." last="Donnelly">Raymond P. Donnelly</name>
<affiliation><inist:fA14 i1="01"><s1>Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration</s1>
<s2>Silver Spring, MD 20993</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Beta interferon</term>
<term>Combined treatment</term>
<term>Cytokine</term>
<term>Drug combination</term>
<term>In vitro</term>
<term>Influenza A</term>
<term>Influenza A virus</term>
<term>Oseltamivir</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>In vitro</term>
<term>Grippe A</term>
<term>Cytokine</term>
<term>Interféron bêta</term>
<term>Oséltamivir</term>
<term>Virus grippal A</term>
<term>Traitement associé</term>
<term>Association médicamenteuse</term>
<term>Antiviral</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza viruses, which can cross species barriers and adapt to new hosts, pose a constant potential threat to human health. The influenza pandemic of 2009 highlighted the rapidity with which an influenza virus can spread worldwide. Currently available antivirals have a number of limitations against influenza, and novel antiviral strategies, including novel drugs and drug combinations, are urgently needed. Here, we evaluated the in vitro effects of interferon (IFN)-β, IFN-λ1, oseltamivir carboxylate (a neuraminidase (NA) inhibitor), and combinations of these agents against two seasonal (i.e., H1N1 and H3N2) influenza A viruses. We observed that A/California/04/09 (H1N1) and A/Panama/2007/99 (H3N2) isolates were equally sensitive to the antiviral activity of IFN-β and oseltamivir carboxylate in A549 and Calu-3 cells. In contrast, IFN-λ1 exhibited substantially lower protective potential against the H1N1 strain (64-1030-fold ↓, P < 0.05), and was ineffective against H3N2 virus in both cell lines. Three dimensional analysis of drug-drug interactions revealed that IFN-λ1 interacted with IFN-β and oseltamivir carboxylate in an additive or synergistic manner, respectively, to inhibit influenza A virus replication in human airway epithelial cells. Overall, the present study demonstrated that anti-influenza agents with different mechanisms of action (e.g., a NA inhibitor combined with IFN-λ1) exerted a significantly greater (P < 0.05) synergistic effect compared to co-treatment with drugs that target the same signaling pathway (i.e., IFN-β plus IFN-λ1) in vitro. Our findings provide support for the combined use of interferon plus oseltamivir as a potential means for treating influenza infections.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0166-3542</s0>
</fA01>
<fA02 i1="01"><s0>ARSRDR</s0>
</fA02>
<fA03 i2="1"><s0>Antivir. res.</s0>
</fA03>
<fA05><s2>111</s2>
</fA05>
<fA08 i1="01" i2="1" l="ENG"><s1>In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ILYUSHINA (Natalia A.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>DONNELLY (Raymond P.)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration</s1>
<s2>Silver Spring, MD 20993</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA20><s1>112-120</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>18839</s2>
<s5>354000502689950160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>3/4 p.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0273479</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral research</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Influenza viruses, which can cross species barriers and adapt to new hosts, pose a constant potential threat to human health. The influenza pandemic of 2009 highlighted the rapidity with which an influenza virus can spread worldwide. Currently available antivirals have a number of limitations against influenza, and novel antiviral strategies, including novel drugs and drug combinations, are urgently needed. Here, we evaluated the in vitro effects of interferon (IFN)-β, IFN-λ1, oseltamivir carboxylate (a neuraminidase (NA) inhibitor), and combinations of these agents against two seasonal (i.e., H1N1 and H3N2) influenza A viruses. We observed that A/California/04/09 (H1N1) and A/Panama/2007/99 (H3N2) isolates were equally sensitive to the antiviral activity of IFN-β and oseltamivir carboxylate in A549 and Calu-3 cells. In contrast, IFN-λ1 exhibited substantially lower protective potential against the H1N1 strain (64-1030-fold ↓, P < 0.05), and was ineffective against H3N2 virus in both cell lines. Three dimensional analysis of drug-drug interactions revealed that IFN-λ1 interacted with IFN-β and oseltamivir carboxylate in an additive or synergistic manner, respectively, to inhibit influenza A virus replication in human airway epithelial cells. Overall, the present study demonstrated that anti-influenza agents with different mechanisms of action (e.g., a NA inhibitor combined with IFN-λ1) exerted a significantly greater (P < 0.05) synergistic effect compared to co-treatment with drugs that target the same signaling pathway (i.e., IFN-β plus IFN-λ1) in vitro. Our findings provide support for the combined use of interferon plus oseltamivir as a potential means for treating influenza infections.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02C</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>In vitro</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>In vitro</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>In vitro</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Grippe A</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Influenza A</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Gripe A</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Cytokine</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Cytokine</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Citoquina</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Interféron bêta</s0>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Beta interferon</s0>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Interferón beta</s0>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Oséltamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Oseltamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Oseltamivir</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Virus grippal A</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Influenza A virus</s0>
<s2>NW</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Traitement associé</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Combined treatment</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Tratamiento asociado</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Drug combination</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Influenzavirus A</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Orthomyxoviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Exo-α-sialidase</s0>
<s2>FE</s2>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Glycosidases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Glycosylases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Hydrolases</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Enzyme</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Enzima</s0>
<s2>FE</s2>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Inhibiteur enzyme</s0>
<s5>38</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Enzyme inhibitor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Inhibidor enzima</s0>
<s5>38</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Inhibiteur neuraminidase</s0>
<s2>FR</s2>
<s5>39</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Neuraminidase inhibitor</s0>
<s2>FR</s2>
<s5>39</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Inhibidor neuraminidas</s0>
<s2>FR</s2>
<s5>39</s5>
</fC07>
<fN21><s1>342</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0273479 INIST</NO>
<ET>In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate</ET>
<AU>ILYUSHINA (Natalia A.); DONNELLY (Raymond P.)</AU>
<AF>Division of Therapeutic Proteins, Center for Drug Evaluation and Research, Food and Drug Administration/Silver Spring, MD 20993/Etats-Unis (1 aut., 2 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Antiviral research; ISSN 0166-3542; Coden ARSRDR; Royaume-Uni; Da. 2014; Vol. 111; Pp. 112-120; Bibl. 3/4 p.</SO>
<LA>Anglais</LA>
<EA>Influenza viruses, which can cross species barriers and adapt to new hosts, pose a constant potential threat to human health. The influenza pandemic of 2009 highlighted the rapidity with which an influenza virus can spread worldwide. Currently available antivirals have a number of limitations against influenza, and novel antiviral strategies, including novel drugs and drug combinations, are urgently needed. Here, we evaluated the in vitro effects of interferon (IFN)-β, IFN-λ1, oseltamivir carboxylate (a neuraminidase (NA) inhibitor), and combinations of these agents against two seasonal (i.e., H1N1 and H3N2) influenza A viruses. We observed that A/California/04/09 (H1N1) and A/Panama/2007/99 (H3N2) isolates were equally sensitive to the antiviral activity of IFN-β and oseltamivir carboxylate in A549 and Calu-3 cells. In contrast, IFN-λ1 exhibited substantially lower protective potential against the H1N1 strain (64-1030-fold ↓, P < 0.05), and was ineffective against H3N2 virus in both cell lines. Three dimensional analysis of drug-drug interactions revealed that IFN-λ1 interacted with IFN-β and oseltamivir carboxylate in an additive or synergistic manner, respectively, to inhibit influenza A virus replication in human airway epithelial cells. Overall, the present study demonstrated that anti-influenza agents with different mechanisms of action (e.g., a NA inhibitor combined with IFN-λ1) exerted a significantly greater (P < 0.05) synergistic effect compared to co-treatment with drugs that target the same signaling pathway (i.e., IFN-β plus IFN-λ1) in vitro. Our findings provide support for the combined use of interferon plus oseltamivir as a potential means for treating influenza infections.</EA>
<CC>002B02S05; 002B05C02C</CC>
<FD>In vitro; Grippe A; Cytokine; Interféron bêta; Oséltamivir; Virus grippal A; Traitement associé; Association médicamenteuse; Antiviral</FD>
<FG>Virose; Infection; Influenzavirus A; Orthomyxoviridae; Virus; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Inhibiteur enzyme; Inhibiteur neuraminidase</FG>
<ED>In vitro; Influenza A; Cytokine; Beta interferon; Oseltamivir; Influenza A virus; Combined treatment; Drug combination; Antiviral</ED>
<EG>Viral disease; Infection; Influenzavirus A; Orthomyxoviridae; Virus; Exo-α-sialidase; Glycosidases; Glycosylases; Hydrolases; Enzyme; Enzyme inhibitor; Neuraminidase inhibitor</EG>
<SD>In vitro; Gripe A; Citoquina; Interferón beta; Oseltamivir; Influenza A virus; Tratamiento asociado; Asociación medicamentosa; Antiviral</SD>
<LO>INIST-18839.354000502689950160</LO>
<ID>14-0273479</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000025 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000025 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0273479
   |texte=   In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate

In vitro anti-influenza A activity of interferon (IFN)-λ1 combined with IFN-β or oseltamivir carboxylate

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri